Measurable residual disease
Detecting residual disease after treatment of blood cancers.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 198, 195, 248, 248, 297.
New guidelines and consensus this year
- B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In OncologyJ Natl Compr Canc Netw2026 Sep
- Consensus Statement on ctDNA Minimal Residual Disease Testing in Early Stage NSCLC: A Delphi Study by the Asian Thoracic Oncology Research GroupJ Thorac Oncol2026 Aug
- NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026J Natl Compr Canc Netw2026 Jun
- [Recommendations from the GBMHM and the Fi-LMC for the diagnosis and management of chronic myeloid leukemia]Bull Cancer2026 Apr
- 2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working PartyBlood2026 Mar 12
All papers from the last 12 months
1,709 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Microhaplotype-based chimerism analysis for sensitive monitoring following allogeneic hematopoietic stem cell transplantationClin Chim Acta2027 Feb 15PMID 42648527
- MicroRNA profiles as diagnostic tools in pediatric acute lymphoblastic leukemiaClin Chim Acta2027 Feb 15PMID 42641935Review
- Digital droplet PCR and liquid biopsy in acute myeloid Leukemia: bridging translational research and clinical practiceClin Chim Acta2027 Feb 15PMID 42624191Review
- Thermal-enhanced atypical suboptimal PAM-dependent CRISPR/Cas12a amplification for detecting BCR1-Type PML::RARα fusion and L217F mutationBiosens Bioelectron2027 Jan 1PMID 42731312
- CRISPR-Cas12a-based liquid biopsy technology: challenges in large-scale clinical applicationClin Chim Acta2027 Jan 1PMID 42379464Review
- TIM-3 as an immune and leukemia stem-cell biomarker in acute myeloid leukemia: diagnostic laboratory and translational perspectivesClin Chim Acta2027 Jan 1PMID 42309212Review
- Frontline therapies for adult patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia: a systematic literature reviewHematology2026 Dec 31PMID 42711755Systematic review
- Serologic follow-up in patients with multiple myeloma without repeated bone marrow studies: a single-institution experienceHematology2026 Dec 31PMID 42685232
- Identification of coilin in bone marrow as a potential neuroblastoma tumor progression marker transcriptionally regulated by MYCNCancer Biol Ther2026 Dec 31PMID 41423806
- A streamlined hybrid-capture and genome-wide multi-omic platform for highly sensitive ctDNA minimal residual disease monitoringJ Liq Biopsy2026 DecPMID 42830887
More hematology trends
All specialties →Bispecific antibodies in myeloma
Teclistamab, elranatamab and talquetamab in multiple myeloma.
Gene therapy for sickle cell and thalassaemia
CRISPR-based and lentiviral gene therapies for haemoglobin disorders.
CAR-T in blood cancers
Chimeric antigen receptor T-cell therapy in lymphoma, myeloma and leukaemia.
Key point: CAR T-cell therapy has emerged as an effective option for refractory or progressive mantle cell lymphoma after prior covalent BTK inhibitor treatment.
Immune thrombocytopenia
ITP and its newer treatments.
Key point: Adult ITP care incorporates newer thrombopoietin receptor agonists and small molecule kinase inhibitors, emphasizing thrombotic risk and quality of life.
DOACs in cancer-associated thrombosis
Direct oral anticoagulants for venous thromboembolism in people with cancer.
Myelofibrosis treatment
JAK inhibitors and newer drugs in myelofibrosis.
Key point: Ruxolitinib-based combination regimens showed improved spleen and symptom responses with acceptable safety, with efficacy significantly influenced by prior JAK inhibitor exposure.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
"measurable residual disease"[tiab] OR "minimal residual disease"[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.